Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Nov;57(11):5258-65.
doi: 10.1128/AAC.01069-13. Epub 2013 Aug 12.

Mutations of the ompK36 porin gene and promoter impact responses of sequence type 258, KPC-2-producing Klebsiella pneumoniae strains to doripenem and doripenem-colistin

Affiliations

Mutations of the ompK36 porin gene and promoter impact responses of sequence type 258, KPC-2-producing Klebsiella pneumoniae strains to doripenem and doripenem-colistin

Cornelius J Clancy et al. Antimicrob Agents Chemother. 2013 Nov.

Abstract

Doripenem-colistin exerts synergy against some, but not all, Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae strains in vitro. We determined if doripenem MICs and/or ompK36 porin gene mutations impacted the responses of 23 sequence type 258 (ST258), KPC-2-producing strains to the combination of doripenem (8 μg/ml) and colistin (2 μg/ml) during time-kill assays. The median doripenem and colistin MICs were 32 and 4 μg/ml. Doripenem MICs did not correlate with KPC-2 expression levels. Five and 18 strains had wild-type and mutant ompK36, respectively. The most common mutations were IS5 promoter insertions (n = 7) and insertions encoding glycine and aspartic acid at amino acid (aa) positions 134 and 135 (ins aa134-135 GD; n = 8), which were associated with higher doripenem MICs than other mutations or wild-type ompK36 (all P values ≤ 0.04). Bactericidal activity (24 h) was achieved by doripenem-colistin against 12%, 43%, and 75% of ins aa134-135 GD, IS5, and wild-type/other mutants, respectively (P = 0.04). Doripenem-colistin was more active in time-kill studies than colistin at 12 and 24 h if the doripenem MIC was ≤8 μg/ml (P = 0.0007 and 0.09, respectively), but not if the MIC was >8 μg/ml (P = 0.10 and 0.16). Likewise, doripenem-colistin was more active at 12 and 24 h against the wild type/other mutants than ins aa134-135 GD or IS5 mutants (P = 0.007 and 0.0007). By multivariate analysis, the absence of ins aa134-135 GD or IS5 mutations was the only independent predictor of doripenem-colistin responses at 24 h (P = 0.002). In conclusion, ompK36 genotypes identified ST258 KPC-K. pneumoniae strains that were most likely to respond to doripenem-colistin.

PubMed Disclaimer

Figures

Fig 1
Fig 1
Nucleotide sequences of the upstream regions of the ompK36 gene in strains with wild-type sequence, a full-length IS5 insertion, and an IS5 insertion along with a promoter deletion. Nucleotide positions shared by the three strains are marked with asterisks; missing bases are indicated by dashes. The ompK36 ribosome binding site (rbs), start codon, and −10 and −35 promoter sequences are shown in boldface, while the presumed IS5 element integration sites (target site duplications [TSD]) are shown in boldface italics. Open reading frames (ORFs) are portrayed by arrows, with the IS5 transposase ORF indicated in black and the upstream ORF (KPHS_37020) and ompK36 ORF in white. The inserted IS5 element, including the IS5 transposase ORF (black arrow) and its right and left inverted repeats (IR-R and IR-L), are shown in gray italic letters. Single-line arrows beneath the inverted repeats indicate the direction of the repeats. A 1,200-bp IS5 element is inserted 33 bp upstream of the ompK36 start code from the TSD site (TTAA), which qRT-PCR data indicate is disrupting the transcription of ompK36. The gray shading denotes a 395-bp deletion region, encompassing a partial sequence of an unknown ORF (KPHS_37020) and the −30 and −10 promoters. The IS5 insertion and promoter deletion also disrupt ompK36 expression.
Fig 2
Fig 2
Killing activity of doripenem (Dori) against KPC-K. pneumoniae strains, stratified by doripenem MICs (A) and the presence of ompK36 mutations (B). The data represent the median log10 kills by doripenem. (A) P values indicate the differences in killing by doripenem against 4 strains with doripenem MICs of ≤8 μg/ml and 19 strains with MICs of >8 μg/ml. (B) P values indicate the differences in killing by doripenem against 8 ins aa134-135 GD mutants, 7 IS5 mutants, and 8 ompK36 other mutant/wild-type strains (ANOVA).
Fig 3
Fig 3
Killing activity of colistin (COL) against KPC-K. pneumoniae strains, stratified by colistin MICs. The data represent median log10 kills by colistin; the P values indicate the differences between KPC-K. pneumoniae strains for which colistin MICs were ≤2 μg/ml and >2 μg/ml.
Fig 4
Fig 4
Killing activities of doripenem, colistin, and colistin-doripenem against KPC-K. pneumoniae strains, stratified by doripenem MICs (A) and the presence of ompK36 mutations (B). The P values indicate the differences in median time kills by colistin versus doripenem-colistin in combination. (A) Median log10 kills by doripenem, colistin, and doripenem-colistin against KPC-K. pneumoniae strains with MICs of ≤8 μg/ml (upper graph) and >8 μg/ml (lower graph). Note the lower level of kills for strains with MICs of >8 μg/ml at each time point. (B) Median log10 kills by doripenem, colistin, and doripenem-colistin against other mutant/wild-type ompK36 strains (upper graph) and strains with ins aa134-135 GD or IS5 mutations (lower graph). Note the lower level of kills for ins aa134-135 GD or IS5 mutants.
Fig 5
Fig 5
Model for predicting responses of KPC-K. pneumoniae strains to doripenem-colistin. The model is based on data demonstrating that lower doripenem MICs were associated with the extent of synergy at 24 h and that the absence of ins aa134-135 GD and IS5 mutations was independently associated with levels of killing and extent of synergy at 24 h.

References

    1. Bratu S, Landman D, Haag R, Recco R, Eramo A, Alam M, Quale J. 2005. Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium. Arch. Intern. Med. 165:1430–1435 - PubMed
    1. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J. 2009. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis. 48:1–12 - PubMed
    1. Nordmann P, Cuzon G, Naas T. 2009. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect. Dis. 9:228–236 - PubMed
    1. Maltezou HC, Giakkoupi P, Maragos A, Bolikas M, Raftopoulos V, Paphatzaki H, Vrouhos G, Liakou V, Vatopouos AC. 2009. Outbreak of infections due to KPC-2-producing Klebsiella pneumoniae in a hospital in Crete (Greece). J. Infect. 58:213–219 - PubMed
    1. Rhee JY, Park YK, Shin JY, Choi JY, Lee MY, Peck KR, Song HG, Ko KS. 2010. KPC-producing extreme drug-resistant Klebsiella pneumoniae isolate from a patient with diabetes mellitus and chronic renal failure on hemodialysis in South Korea. Antimicrob. Agents Chemother. 54:2278–2279 - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources